The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor

International Journal of Clinical Practice

Volumn 62, Issue 12, 2008, Pages 1844-1850

  Jones, R ^a,b   Patrikios, T ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BALANCE DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE;

ANTI-ULCER AGENTS; CHRONIC DISEASE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; RECURRENCE; TREATMENT OUTCOME;

EID: 55949102329     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01923.x     Document Type: Article

References (18)

1. Dent J, El-Serag H, Wallanger M. Epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2005 54 : 710 7.
2. Kulig M, Leodolter A, Vieth M et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003 18 : 767 76.
3. Wiklund I, Carlsson J, Vakil N. Gastro-esophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006 101 : 18 28.
4. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2004 4, Art. No.: CD003245. doi :.
5. Jones R, Armstrong D, Malfertheiner P et al. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study Curr Med Res Opin 2006 22 : 657 62.
6. Fass R, Shapiro M, Dekel R et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94.
7. National Institute for Clinical Excellence (NICE). Clinical Guideline 17 Dypspesia - Management of Dyspepsia in Adults in Primary Care. http://www.nice.org.uk (accessed August 2004).
8. Jones R, Liker HR, Ducrotte P. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007 61 : 1301 7.
9. McColl E, Junghard O, Wiklund I, Revicki D. Assessing symptoms in gastro-esophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005 100 : 11 8.
10. Jones R, Coyne K, Wiklund I. The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007 25 : 1451 9.
11. Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than iansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60 : 531 9.
12. Wilder-Smith C, Lind T, Lundin C et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007 42 : 157 64.
13. Miner P, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a 5-way crossover study. Am J Gastroenterol 2003 98 : 2616 20.
14. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2007 24 : 743 50.
15. Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000 14 : 1249 58.
16. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive oesophagitis. Am J Gastroenterol 2002 97 : 575 83.
17. Shaw MJ, Talley NJ, Beebe TJ et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001 96 : 52 7.
18. Khan M, Santant J, Donellan C. High dose versus standard dose proton pump inhibitors in the short term management of reflux esophagitis. Gastroenterology 2006 130 (4 Suppl. 2 177, Abs S1210.